Abstract:Background: Perinatal stroke refers to a diverse but specific group of cerebrovascular diseases that occur between 20 weeks of fetal life and 28 days of postnatal life. Acute treatment options for perinatal stroke are limited supportive care, such as controlling hypoglycemia and seizures. Stem cell-based therapies offer a potential therapeutic approach to repair, restore, or regenerate injured brain tissue. Preclinical findings have culminated in ongoing human neonatal studies. Objectives: To evaluate the benefits and harms of stem cell-based interventions for the treatment of stroke in newborn infants compared to control (placebo or no treatment) or stem-cell based interventions of a different type or source. Search methods: We searched CENTRAL, PubMed, Embase, and three trials registries in February 2023. We planned to search the reference lists of included studies and relevant systematic reviews for studies not identified by the database searches. Selection criteria: We attempted to include randomized controlled trials, quasi-randomized controlled trials, and cluster trials that evaluated any of the following comparisons. • Stem cell-based interventions (any type) versus control (placebo or no treatment) • Mesenchymal stem/stromal cells (MSCs) of a specifictype (e.g. number of doses or passages) or source (e.g. autologous/allogeneic or bone marrow/cord) versus MSCs of another type or source • Stem cell-based interventions (other than MSCs) of a specific type (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, or induced pluripotent stem cell-derived cells) or source (e.g. autologous/allogeneic or bone marrow/cord) versus stem cell-based interventions (other than MSCs) of another type or source • MSCs versus stem cell-based interventions other than MSCs We planned to include all types of transplantation regardless of cell source (bone marrow, cord blood, Wharton's jelly, placenta, adipose tissue, peripheral blood), type of graft (autologous or allogeneic), and dose. Data collection and analysis: We used standard Cochrane methods. Our primary outcomes were all-cause neonatal mortality, major neurodevelopmental disability, and immune rejection or any serious adverse event. Our secondary outcomes included all-cause mortality prior to first hospital discharge, seizures, adverse effects, and death or major neurodevelopmental disability at 18 to 24 months of age. We planned to use GRADE to assess the certainty of evidence for each outcome. Main results: We identified no completed or ongoing randomized trials that met our inclusion criteria. We excluded three studies: two were phase 1 trials, and one included newborn infants with conditions other than stroke (i.e. cerebral ischemia and anemia). Among the three excluded studies, we identified the first phase 1 trial on the use of stem cells for neonatal stroke. It reported that a single intranasal application of bone marrow-derived MSCs in term neonates with a diagnosis of perinatal arterial ischemic stroke (PAIS) was feasible and apparently not associated with severe adverse events. However, the trial included only 10 infants, and follow-up was limited to three months. Authors' conclusions: No evidence is currently available to evaluate the benefits and harms of stem cell-based interventions for treatment of stroke in newborn infants. We identified no ongoing studies. Future clinical trials should focus on standardizing the timing and method of cell delivery and cell processing to optimize the therapeutic potential of stem cell-based interventions and safety profiles. Phase 1 and large animal studies might provide the groundwork for future randomized trials. Outcome measures should include all-cause mortality, major neurodevelopmental disability and immune rejection, and any other serious adverse events.

Stem Cell Therapy in Neonatal Hypoxic-Ischemic Encephalopathy and Cerebral Palsy: a Bibliometric Analysis and New Strategy

Human Neural Stem Cell Grafts Modify Microglial Response and Enhance Axonal Sprouting in Neonatal Hypoxic–Ischemic Brain Injury

Research on Stem Cell Therapy for Spinal Cord Injury: a Bibliometric and Visual Analysis from 2018–2023

A Visualization Analysis of Current Research on Stem Cell Transplantation in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

Stem Cells in Central Nervous System Diseases: Promising Therapeutic Strategies.

The fate and prospects of stem cell therapy in the treatment of hypoxic‐ischemic encephalopathy

Stem Cell Therapy for Neonatal Hypoxic-Ischemic Encephalopathy: A Systematic Review of Preclinical Studies

Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis

Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers

Bibliometric Analysis of Stem Cells in Ischemic Stroke (2001-2022): Trends, Hotspots and Prospects

Progress in Research on Stem Cells in Neonatal Refractory Diseases

The global state of research in stem cells therapy for spinal cord injury (2003–2022): a visualized analysis

Transplantation of Neural Stem Cells, Schwann Cells and Olfactory Ensheathing Cells for Spinal Cord Injury : A Web of Science-based Literature Analysis.

Stem cell-based interventions for the treatment of stroke in newborn infants

Mesenchymal stem cells for peripheral nerve injury and regeneration: a bibliometric and visualization study

The Starus of Cell Therapy for Cerebral Palsy

Research hotspots and frotiers of stem cells in stroke: A bibliometric analysis from 2004 to 2022

Progress in Clinical Trials of Stem Cell Therapy for Cerebral Palsy

Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer's Disease from 2004 to 2022

Advances in mesenchymal stem cell-centered stem cell therapy in the treatment of hypoxic-ischemic injury

Current analysis of hypoxic-ischemic encephalopathy research issues and future treatment modalities